Supernus Pharmaceuticals reported a strong second quarter in 2020, with total revenue reaching $126.7 million, driven by net product sales of Trokendi XR, Oxtellar XR, and acquired Parkinson’s disease products. The company also completed the acquisition of the CNS portfolio of US WorldMeds and executed a Development and Option Agreement with Navitor Pharmaceuticals, Inc.
Total revenue reached $126.7 million, including $10.6 million from acquired Parkinson’s disease (PD) products.
Operating earnings were $45.5 million.
Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020.
Reinstating and updating full year 2020 financial guidance, inclusive of the impact of acquiring the PD products as of June 9, 2020.
Supernus is reinstating and updating its full year 2020 financial guidance, inclusive of the impact of acquiring the PD products as of June 9, 2020.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance